Navigation Links
Schering-Plough Initiates Phase III Studies with Vicriviroc in Treatment- Experienced HIV Patients
Date:9/17/2007

Next-Generation Once-Daily CCR5 Antagonist Designed to Block HIV Infection

of Immune System Cells

KENILWORTH, N.J., Sept. 17 /PRNewswire-FirstCall/ -- Schering-Plough Corporation (NYSE: SGP) today announced that it has initiated two large Phase III clinical studies with vicriviroc, its investigational CCR5 antagonist, administered once-daily as a single 30 mg tablet in combination with an optimized background therapy that must include a protease inhibitor boosted by ritonavir in adult treatment-experienced HIV patients with R5-type virus only. Vicriviroc is a next-generation extracellular inhibitor of HIV infection designed to block entry of infectious virions into uninfected CD4 cells via antagonism of the CCR5 co-receptor.

The vicriviroc Phase III clinical program builds upon previous studies in HIV treatment-experienced patients, including a Phase II study (ACTG 5211) in which vicriviroc demonstrated potent and sustained viral suppression through 48 weeks of therapy.(1)

The two Phase III studies, known as VICTOR-E3 and VICTOR-E4 (Vicriviroc in Combination Treatment with an Optimized Antiretroviral Therapy Regimen in HIV- Infected Treatment-Experienced Subjects), will evaluate the virologic benefit of adding vicriviroc 30 mg once daily to an optimized background therapy compared to a control group receiving new optimized background therapy alone. The studies will also evaluate the safety and tolerability of vicriviroc compared to placebo. The optimized background therapy must include at least two drugs that are active, based on susceptibility testing. Patients coinfected with hepatitis C may be included in the studies and there are no exclusions of commonly prescribed drug
'/>"/>

SOURCE Schering-Plough Corporation
Copyright©2007 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine technology :

1. Schering-Plough Announces Hepatitis C Data Presentations at Digestive Disease Week (DDW) 2007 Annual Meeting
2. Schering-Plough Addresses Major Milestones and Challenges in Treatment of Patients With Chronic Hepatitis C
3. Schering-Plough Announces Presentation of Phase II Trial Results for Novel Oral Thrombin Receptor Antagonist at the 2007 Annual Meeting of The American College of Cardiology/i2 Summit
4. Malvern initiates European user group meetings for chemical imaging
5. Data Available From Erbitux Phase III Study in First-Line Treatment of Advanced Lung Cancer
6. Phase 3 Results for Dabigatran Etexilate, an Investigational Oral Anticoagulant, Presented Today at the XXIst Congress of the International Society on Thrombosis and Haemostasis
7. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
8. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
9. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
10. Actemra (tocilizumab) Third Phase III Study Results Show Significant Improvement in Symptoms of Patients with Rheumatoid Arthritis
11. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/6/2009)...RSIPPANY, N.J., Jan. 6 Pacira Phar...ceutical company, announced today that enrollment,...E trials to evaluate the,safety and efficacy of a...M),(DepoBupivacaine) for prolonged postoperative ...morrhoidectomy and in total knee,arthroplasty (TK...
(Date:1/5/2009)...THESDA, Md., Jan. 5 Micr... company developing novel, proprietary,antibodies...oimmune diseases,provides an outlook on key even...met intends to provide an update on its research a..., -- April 12 to 16, 2009: Update on severa...
(Date:12/30/2008)...GTON, Dec. 30 The Coali...e citizen petition filed by Genentech, Inc. on Dec...laboratories to offer diagnostic tests to physicia... in laboratory tests, would harm patient care and ... , The Coalition,s mission is to encourage the re...
(Date:12/27/2008)...N DIMAS, Calif., Dec. 27 According...e best advised to consume modest doses of,resvera...ically provided in 3,to 5 glasses of aged, red wi...: http://www.newscom.com/cgi-bin/prnh/20080603/L...a-dose resveratrol alone fails to prolong,the lif...
Breaking Medicine Technology:Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 2Phase III Studies of EXPAREL(TM) (DepoBupivacaine) from Pacira Complete Enrollment 3Micromet Key Events for 2009 2Micromet Key Events for 2009 3Micromet Key Events for 2009 4Micromet Key Events for 2009 5Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 2Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 3Coalition for 21st Century Medicine Issues Statement in Opposition of Genentech Petition to Restrict Lab Use of Diagnostic Tests for Physicians and Patients 4Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 2Longevity Seekers Advised to Consume Modest Doses of Red Wine Molecules in Dietary Supplements (Longevinex(R)) Rather than Mega-Dose Resveratrol Alone 3Molecular Breast Imaging Identifies Occult Cancer 31228 1Molecular Breast Imaging Identifies Occult Cancer 31228 2Sigma Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT 28R 29 Single Wall Carbon Nanotubes 9489 1Sigma Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT 28R 29 Single Wall Carbon Nanotubes 9489 2Sigma Aldrich Signs Agreement With SouthWest NanoTechnologies to Distribute SWeNT 28R 29 Single Wall Carbon Nanotubes 9489 3Drink Brewed Tea to Avoid Tooth Erosion 31224 1Drink Brewed Tea to Avoid Tooth Erosion 31224 2Drink Brewed Tea to Avoid Tooth Erosion 31224 3Prostate Cancer Stimulates Nerve Growth 31221 1Prostate Cancer Stimulates Nerve Growth 31221 2
...ARLSBAD, CA, May 31, 2007 /PRNewswire-FirstCall/,-...als, Inc. today,announced that preliminary data fr...sented at the American Society of Clinical,Oncolog...e data,from a Phase II clinical study of OGX-011 i... a Phase I/II clinical study of,OGX-011 in non-sma...
...t the Pediatric Academic Societies, Annual Meeting...imo SET Pulse,Oximetry Technology Can Reduce the R...y 30, 2007 /PRNewswire/ -- Masimo, the,inventor of...,Perfusion pulse oximetry, reported that a new ind... Societies, (PAS) Annual Meeting,in Toronto, Canad...
Other Medicine Technology:OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO 2OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO 3OncoGenex and Isis Announce OGX-011 Data to be Presented at ASCO 4Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology,Shown to Significantly Lower Instances of Severe Retinopathy of,Prematurity in Extremely Low Birth Weight Infants 2Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology,Shown to Significantly Lower Instances of Severe Retinopathy of,Prematurity in Extremely Low Birth Weight Infants 3Breaking Multi-Center Study: Masimo SET Pulse Oximetry Technology,Shown to Significantly Lower Instances of Severe Retinopathy of,Prematurity in Extremely Low Birth Weight Infants 4
(Date:1/8/2009)...swire/ -- Today, the National Hospice and Palliati...eadership organizations issued a consensus stateme...otection of the Medicare Hospice Benefit. The orga...d message about end-of-life care are the American ...spice and Palliative Nurses Association, National ...
(Date:1/8/2009)...f cancer cells are keys to the development of a ne...spread of certain types of cancers called carcinom...ng, among others. Armed with a new two-year grant..., an Illinois-based philanthropic foundation, immu...o-workers at the Moores Cancer Center at the Unive...
(Date:1/8/2009)...or in Decision for Florida Multi-Specialty Group ...re-FirstCall/ -- Allscripts announced today that P...specialty group practices in the Southeast United ... Electronic Health Record (EHR) to automate and co...tral Florida. , , (Logo: http://www.newscom....
(Date:1/8/2009)...ce to raise money for Camp Courage at Mall of Amer... , , WHO: Dance students., WHAT:...rd annual Dance, with Courage Danc... event will be emceed by Tom Butler, Fox ...ts raise money through pledges to benefit Camp, ...
Breaking Medicine News(10 mins):Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 2Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 3Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 4Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 5Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 6Health News:National End-of-Life Organizations Release Consensus Statement on Hospice, the Medicare Hospice Benefit, and Key Issues for the Future 7Health News:Novel prostate cancer vaccine taking aim at cancer cell 'sweet spot' 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 2Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 3Health News:Physician Associates, LLC Selects Allscripts Electronic Health Record to Connect and Automate 80 Physicians 4Health News:Dance With Courage to Benefit Camp Courage 2
...line by Developmental Biology, members of Dr. John...ealth System report the discovery// of a new prote...rget for male contraceptive drugs. “There’s consi...e contraceptives,” said Herr, who heads UVa’s Cent...
... greying process continues with gusto into the 21s...uthfulness always pouts with tantalising// appeal....t the secret is enmeshed in DNA. If the DNA within...ging process of an individual. This is especially ...
...cussions of a potential flu pandemic showed that n...om the underprivileged nations, could pay// with t...he infamous 1918 Spanish flu, which wiped out near.... Researchers from the Harvard School of Public He...
... the years ahead, medical science miracles will be...e for various treatments will stand to// reshape t...of the health-planning department at Eastern Virgi...e in the British Medical Journal based on these te...
Other Medicine News:Health News:Male Contraception: Discovery Stirring Interest Among Scientists, Drug Developers 2Health News:Clues to Allay Aging 2Health News:Medical Science Miracles – Coming Your Wa 2
Stat Detection of Soluble Fibrin Monomer Complexes by the Hemagglutination Technique, 32 tests.
For use with catalog #0540.
Immuno-turbidimetric Assay of D-Dimer by STA© Analyzers. Microlatex particles coated with two different mouse monoclonal anti-human D-Dimer antibodies.
Antigenic Free Protein S, ELISA Method
Medicine Products: